Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-913-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Acute oral toxicity (method similar to OECD TG 401): LD50 >5000 mg/kg bw
Acute oral toxicity : LD50 >2000 mg/kg bw
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- July 1971
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Remarks:
- pre-GLP
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- clear colorless liquid SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: research Institute for Fragrance Materials
-RIFM number: 56452 - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 150-300 g
- Fasting period before study: overnight - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 50% (v/v)
- Justification for choice of vehicle: according to guideline - Doses:
- 5000 mg/kg bw
- No. of animals per sex per dose:
- 10
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: toxic signs and mortality were observed forllowing dosing at one and four hours, and once daily thereafter.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs - Preliminary study:
- Two aninals were given a single dose by gastric intubation. No deaths occured, so 8 additional animals were given the samen dose via the same route.
- Key result
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No
- Clinical signs:
- other: Signs of diahrrea, depression and piloerection were observed.
- Gross pathology:
- No gross findings
- Interpretation of results:
- other: not classied
- Remarks:
- based on CLP criteria (Annex I 1272/2008/EC)
- Conclusions:
- The oral LD50 value of Copaiba balsam oil in rats was established to be higher than 5000 mg/kg bw, under the conditions of this study. The substance therefore does not need to be classified for acute oral toxicity according to the criteria laid down in Annex I of 1272/2008/EC (CLP).
- Executive summary:
The acute toxic potential of Copaiba Balsam oil was assessed in an acute oral toxicity limit test performed in 10 rats. The rats were exposed to 5000 mg/kg bw Copaibla balsam oil via the oral route, and observed for clinical signs and mortality over an examination period of 14 days. Observations were performed at one and four hours and daily thereafter. At the end of the study period no mortality was observed in any of the animals. Symptoms observed in the test animals were diarrhea, depression, piloerection. No gross findings were noted. The LD50 for acute oral toxicity was set at >5000 mg/kg bw.
Based on these results Copaiba Balsam oil does not have to be classified for acute oral toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1988
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- - Principle of test:medical properties of oleoresin were assessed, investigating the ant-inflammatory activity of the oleoresin, when administered by oral route on various animal models and have concomitantly tested its toxcicological effects. Models used were: Assessment of Carrageening-induced edeema, Cotton-pellet granuloma, Vasculair permeability, and determination of Toxicity
- GLP compliance:
- no
- Test type:
- fixed dose procedure
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Name: Copaiba oleoresin (oleoresin from Brazilian copaifera species)
- Source: The oleoresin was obtained from the Brazilian state of Pará by the Discipline of Pharmacognosy of the Faculty of Pharmaceutical Sciences of São Paulo University.
OTHER SPECIFICS:
-Viscous liquid, aromatoc odor dark brown
-Constituents were determined through GC and identified quantitatively by MS
-Refractive index (25°C) 1.5088
-Specific gravity (25°C) 0.9751 - Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Diet: Fasted, normal diet was Nuvilab CR-1 (Nutrivital)
- Water: ad libitum
- Weight at study initiation: 180 +- 10 grams - Route of administration:
- oral: unspecified
- Vehicle:
- not specified
- Details on oral exposure:
- Not specified
- Doses:
- Carrageenin-induced edema: 0.7, 0.98, 1.37, 1.92, 2.96 ml/kg; (0.68, 0.96, 1.34, 1.87, 2.87 g/kg bw)
Cotton-pellet granuloma: 1.26 ml/kg bw; (1.23 g/kg bw)
Vasculair permeability: 1.26 ml/kg bw (1.23 g/kg bw) - No. of animals per sex per dose:
- Not specified. (For granuloma tisue formation N=10, For vasculair permeability N=6, For determination of toxicity N=20.)
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: Animals were observed for 72 hours for toxicity
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, histopathology, paw- volume, macroscopy of granulomatous tissue, subcutaneous tissue. - Statistics:
- The LD50 was estimated by the method of Thompson and Weil (1951). Analysis of variance with one-way classification was used; sequesntial differences among means were calculated at a level of P < 0.05, using Yukey contrast analysis (Sokal and Rolhf, 1969).
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3.79 mL/kg bw
- Based on:
- test mat.
- 95% CL:
- > 3.21 - < 4.47
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3 670 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 3 130 - < 4 360
- Mortality:
- Not specified
- Clinical signs:
- other: See below
- Gross pathology:
- Development of carrageenin induced pedal edema in dose-dependent manner. assessment of granulomaeous tissue revealed inhobitory effect. Effects in subcutaneous tissue were wignificant reduced permeability increase.
- Other findings:
- Effects of subacute toxicity on day 18, of experimental period the groups treated with 1.92 and 2.86 ml/kg showed a reduction in respect to body weight and in the consumption of food when compared to control group. The efffects were accompanied by diahrrea, sialorrhea, symptoms of depression and gastric irriation consisting of elongated red bands on stomach.
- Interpretation of results:
- other: not classified
- Remarks:
- based on CLP criteria (Annex I 1272/2008/EC)
- Conclusions:
- The oral LD50 value of Copaiba oleoresin in rats was calculated to be >2000 mg/kg bw (3.79 ml/kg bw) under the conditions of this study. Based on these results Copaiba oleoresin does not have to be classified for acute oral toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
- Executive summary:
The acute toxic potential of Copaiba oleoresin was assessed in various animal models. The rats were exposed to doses of 0.7, 0.98. 1.37, 1.92 and 2.96 ml/kg bw (0.68, 0.96, 1.34, 1.87, 2.87 g/kg bw, assessment of Carrageenin-induced edema), and to 1.26 ml/kg bw; (1.23 g/kg bw) to assess Cotton-pellet granuloma and Vasculair permeability via the oral route. Sub-acute symptoms observed in the test animals were for the higher doses reduction in respect to body weight and in the consumption of food. The effects were accompanied by diahrrea, sialorrhea, symptoms of depression and gastric irriation. The oral LD50 value of Copaiba oleoresin in rats was calculated to be >2000 mg/kg bw (3.79 ml/kg bw) under the conditions of this study. Based on these results Copaiba oleoresin does not have to be classified for acute oral toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Acute toxicity, oral (Hart 1971)
The acute toxic potential of Copaiba Balsam oil was assessed in an acute oral toxicity limit test performed in 10 rats. The rats were exposed to 5000 mg/kg bw Copaibla balsam oil via the oral route, and observed for clinical signs and mortality over an examination period of 14 days. Observations were performed at one and four hours and daily thereafter. At the end of the study period no mortality was observed in any of the animals. Symptoms observed in the test animals were diarrhea, depression, piloerection. No gross findings were noted. The LD50 for acute oral toxicity was set at >5000 mg/kg bw. Based on these results Copaiba Balsam oil does not have to be classified for acute oral toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Acute toxicity, oral (Basile 1988)
The acute toxic potential of Copaiba oleoresin was assessed in various animal models. The rats were exposed to doses of 0.7, 0.98. 1.37, 1.92 and 2.96 ml/kg bw (0.68, 0.96, 1.34, 1.87, 2.87 g/kg bw, assessment of Carrageenin-induced edema), and to 1.26 ml/kg bw; (1.23 g/kg bw) to assess Cotton-pellet granuloma and Vasculair permeability via the oral route. Sub-acute symptoms observed in the test animals were for the higher doses reduction in respect to body weight and in the consumption of food. The effects were accompanied by diahrrea, sialorrhea, symptoms of depression and gastric irriation. The oral LD50 value of Copaiba oleoresin in rats was calculated to be >2000 mg/kg bw (3.79 ml/kg bw) under the conditions of this study. Based on these results Copaiba oleoresin does not have to be classified for acute oral toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
